REDACTED PUBLIC VERSION

EXHIBIT A

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
1.	January 28, 2020	Leronlimab Under Evaluation for Potential Treatment of Coronavirus	[redacted]
2.	February 10, 2020	CytoDyn Signs Letter of Intent for the Joint Development and Licensing of Leronlimab in China with Longen China Group	
3.	March 8, 2020	CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140)	
4.	March 13, 2020	CytoDyn Appoints Jacob Lalezari, M.D. as Interim Chief Medical Officer	
5.	March 16, 2020	CytoDyn Files Modified IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab	

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
		(PRO 140) and Advises Correction to Press Release Issued on March 12, 2020	[redacted]
6.	March 23, 2020	Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn's Leronlimab, Bringing the Total to Four Patients	[redacted]
7.	March 27, 2020	Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation	[redacted]
8.	March 27, 2020	CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation	[redacted]
9.	March 30, 2020	Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients	[redacted]

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
			[redacted]
10.	March 31, 2020	FDA Clears CytoDyn's Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately	
11.	April 1, 2020	CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks	
12.	April 2, 2020	Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients	
13.	April 6, 2020	First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated	
14.	April 7, 2020	CytoDyn Collaborating with U.K.'s Department of Health to Provide Emergency Access to Leronlimab for Severe and Critically Ill COVID-19 Patients	
15.	April 7, 2020	Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn's Leronlimab	
16.	April 9, 2020	Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly	

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
		Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7	
17.	April 9, 2020	Severely Ill COVID-19 Patient at Leading Southern California Medical Center Extubated Three Days After Treatment with CytoDyn's Leronlimab; Two Moderate COVID-19 Patients Removed from External Oxygen Following One Day of Treatment with Leronlimab and Discharged from Hospital	[redacted]
18.	April 13, 2020	CytoDyn Appoints Scott A. Kelly, M.D., as Chief Medical Officer and Head of Business Development	[redacted]
19.	April 13, 2020	Southern California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3 Patients Discharged from Hospital; 1 Patient Scheduled for Discharge Today; 1 Patient with Severe Indications Discharged, for Total of 5 Patients Discharged	[redacted]
20.	April 15, 2020	First Patient Treated with Leronlimab in Phase 2b/3 Trial for COVID-19	[redacted]
21.	April 27, 2020	CytoDyn Announces Vyrologix as Proprietary Name for Leronlimab as a	[redacted]

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
		Combination Therapy for Highly Treatment Experienced HIV Patients in the United States	[redacted]
22.	April 30, 2020	CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries	[redacted]
23.	May 4, 2020	FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of May	
24.	May 6, 2020	Manuscript Describes How CytoDyn's Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients	[redacted]
25.	May 7, 2020	Novant Health Initiates Phase 2b/3 Trial with CytoDyn's Leronlimab for Severely and Critically Ill COVID-19 Patients	[redacted]

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
26.	May 15, 2020	CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19	[redacted]
27.	May 18, 2020	CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir	[redacted]
28.	May 19, 2020	CytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population	[redacted]
29.	June 11, 2020	CytoDyn Reached Its Enrollment Target for Phase 2 COVID-19 Trial for Mild to Moderate Indication – Primary End Point Announcement Is Next	[redacted]
30.	June 29, 2020	CytoDyn and NIH of Mexico Complete Memorandum of Understanding to Conduct Small Covid-19 Phase 3 Trial for Severe and Critically Ill Patients	[redacted]
31.	July 3, 2020	CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United States	[redacted]
32.	July 21, 2020	Impressive Results From CytoDyn's Phase 2 Covid-19 Trial	[redacted]

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
33.	July 21, 2020	UPDATE - Impressive Results From CytoDyn's Phase 2 Covid-19 Trial	[redacted]
34.	August 4, 2020	CytoDyn Receives Positive DSMC Recommendation for Leronlimab Phase 3 COVID-19 Trial with No Safety Concerns	[redacted]
35.	August 7, 2020	CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19	[redacted]
36.	August 11, 2020	CytoDyn Announces Clinically Significant Top-line Results from its Phase 2 Trial in Mild-to-Moderate COVID-19 Patients	[redacted]
37.	August 17, 2020	CytoDyn Submits its Top-line Report from its Phase 2 COVID-19 Trial to the U.S. FDA and Requests Emergency Use Approval	[redacted]
38.	August 20, 2020	After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.'s MHRA Accepts CytoDyn's Request to Enroll in its Current Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms	[redacted]
39.	October 12, 2020	CytoDyn Appoints Chiral Pharma to Secure Leronlimab for Local FDA Approval in Philippines	[redacted]

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
40.	October 20, 2020	CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b/3 COVID-19 Registrational Trial	[redacted]
41.	October 26, 2020	U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy	[redacted]
42.	November 11, 2020	CytoDyn Completes Second Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Help Expedite License Applications Here and Abroad and Successful COVID-19 Trials	[redacted]
43.	November 17, 2020	CytoDyn Files Protocol with U.S. FDA for Phase 2 Clinical Trial for COVID-19 Patients with Long-Hauler Symptoms	[redacted]
44.	November 23, 2020	CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This Year	[redacted]
45.	December 15, 2020	CytoDyn Completes Enrollment for Phase 3 Registrational Trial for 390 Patients with Severe-to-Critical COVID-19	[redacted]
46.	December 24, 2020	FDA Provides Guidance for Adding an Open-Label Extension to CytoDyn's Phase 3	[redacted]

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
		Trial for Severe-to-Critical COVID-19 Patients Until Trial Data is Unblinded	
47.	December 30, 2020	FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn's Phase 3 Trial for Severe-to-Critical COVID-19 Patients	
48.	December 31, 2020	CytoDyn Announces Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity	
49.	February 22, 2021	CytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients	
50.	March 5, 2021	CytoDyn's Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab	
51.	March 8, 2021	CytoDyn's Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab	
52.	March 29, 2021	Remarkable Turnaround Following Leronlimab Treatment in Critically Ill COVID-19 Patient After 84 days on ECMO;	

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
		Case Study Published in Journal of Translational Autoimmunity	[redacted]
53.	March 29, 2021	The Philippines FDA Approves the Use of Leronlimab to Treat a COVID-19 Patient	[redacted]
54.	March 30, 2021	CytoDyn's Leronlimab Decreased Mortality at 14 Days by 82% With Statistically Significant P-Value of 0.0233 Amongst Critically Ill COVID-19 Patients	[redacted]
55.	April 1, 2021	CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 Patients with the Objective to Duplicate or Surpass 82% Survival Benefit with P-Value of 0.0233 Originally Achieved from Two Weeks of Treatment in CD12 Trial With 2 Doses	[redacted]
56.	April 5, 2021	First Compassionate Special Permit (CSP) Patient in Philippines Improved Significantly 35 hours After First Injection of Leronlimab and Released 3 Days Later	[redacted]
57.	April 7, 2021	CytoDyn Providing Leronlimab to a Philippine Hospital for 28 More COVID-19 Patients under Compassionate Special Permit (CSP)	

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
			[redacted]
58.	April 7, 2021	CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications	[redacted]
59.	April 8, 2021	CytoDyn's COVID-19 Long-Hauler's Trial Closed as Enrollment Exceeds Goals	[redacted]
60.	April 15, 2021	CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to Provide Up to 200,000 vials of Leronlimab to Philippines	
61.	April 19, 2021	Former President of the Philippines, Joseph Estrada, Among the Many COVID-19 Patients Receiving Leronlimab Under CSP in the Philippines	[redacted]
62.	April 22, 2021	CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants	[redacted]
63.	May 3, 2021	CytoDyn HIV Indication Update: Leronlimab HIV Extension Arm Nearing 7 Years with Continued Excellent Safety Results	

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
			[redacted]
64.	May 5, 2021	CytoDyn Reaches Agreement with Albert Einstein Israelite Hospital in Brazil to Conduct Two COVID-19 Trials - a Small Trial in Critically Ill and a Large Trial in Severe Populations	
65.	May 13, 2021	CytoDyn Signs Distribution Agreement with Macleods Pharmaceuticals Ltd. To Pursue EUA and Compassionate Use Access to Leronlimab in India	
66.	May 18, 2021	CytoDyn to Submit Newly Completed Topline Report of CD12 Trial Results to Regulatory Agencies in Multiple Countries including India and Philippines	
67.	May 27, 2021	Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil in the Next Few Days	
68.	June 1, 2021	CytoDyn and Philippine Airlines Work Together to Provide Filipinos with the Best Possible Treatment Options In the Fight Against Covid-19	
69.	June 21, 2021	CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms	

No.	Date	Title	Drafted/Reviewed/Edited/Approved/Disseminated
70.	July 6, 2021	CytoDyn Granted a Significant Patent by USPTO for Methods of Treating Coronavirus Infection with Leronlimab	[redacted]
71.	August 3, 2021	CytoDyn Receives Clearance from Brazil's ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients	[redacted]
72.	September 9, 2021	CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms	[redacted]
73.	October 7, 2021	CytoDyn Announces Legal Actions Against its Former CRO, Amarex Clinical Research	[redacted]
74.	October 25, 2021	CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 Trial for Critically Ill COVID-19 Patients in Brazil	[redacted]